UPDATE: Goldman Sachs Starts Horizon Pharma (HZNP) at Buy

September 28, 2017 6:49 AM EDT
Get Alerts HZNP Hot Sheet
Price: $112.95 +0.78%

Rating Summary:
    15 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 25 | New: 91
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
(Updated - September 28, 2017 6:58 AM EDT)

(updated to add analyst comment)

Goldman Sachs initiates coverage on Horizon Pharma (NASDAQ: HZNP) with a Buy rating and a price target of $16.00.

Analyst Dana Flanders says the company continues to generate strong cash flow and is allocating capital to differentiated orphan and specialty assets which should drive LT top line growth and margins.

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $12.51 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Goldman Sachs